CONCLUSIONS	The present study provides evidence of the efficacy of Nalpha-methylhistamine , given subcutaneously at doses of 1 to 3 ng twice a week , offering a new therapeutic alternative and laying the clinical and pharmacological groundwork for the use of histaminergic H3-agonists in migraine prophylaxis , which may specifically inhibit the neurogenic edema response involved in migraine pathophysiology .\